New hope for advanced endometrial cancer: Triple-Drug combo enters safety testing
NCT ID NCT05106127
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemotherapy. Researchers will monitor side effects and tolerability, and participants who do well may continue treatment long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EG-007 (a repurposed drug) plus lenvatinib and pembrolizumab
What this could lead to
If successful, this could provide a new treatment option for advanced endometrial cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase safety study with only 28 participants. It is not yet recruiting, so results are uncertain. Adding a third drug may increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.